Clinical trials
HR-positive, HER2-negative Advanced Breast Cancer clinical trials
Below are recruiting hr-positive, her2-negative advanced breast cancer clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT03417115Recruiting
Breast cancer registry study of treatment and outcomes
This is a registry study that collects real-world information about breast cancer care at the start of treatment. It may help researchers better understand which treatments work best for different groups of people.
Many LocationsAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+
Hear when a new HR-positive, HER2-negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hr-positive, her2-negative advanced breast cancer?
- Yes. Clin2 currently lists 29 recruiting hr-positive, her2-negative advanced breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hr-positive, her2-negative advanced breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hr-positive, her2-negative advanced breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- HER2-positive Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Metastatic Breast Cancer
- Advanced HR+/HER2- Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.